GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nova Mentis Life Science Corp (XCNQ:NOVA) » Definitions » Quick Ratio

Nova Mentis Life Science (XCNQ:NOVA) Quick Ratio : 0.03 (As of Mar. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Nova Mentis Life Science Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Nova Mentis Life Science's quick ratio for the quarter that ended in Mar. 2024 was 0.03.

Nova Mentis Life Science has a quick ratio of 0.03. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Nova Mentis Life Science's Quick Ratio or its related term are showing as below:

XCNQ:NOVA' s Quick Ratio Range Over the Past 10 Years
Min: 0.03   Med: 2.65   Max: 17.54
Current: 0.03

During the past 13 years, Nova Mentis Life Science's highest Quick Ratio was 17.54. The lowest was 0.03. And the median was 2.65.

XCNQ:NOVA's Quick Ratio is ranked worse than
98.44% of 1540 companies
in the Biotechnology industry
Industry Median: 3.58 vs XCNQ:NOVA: 0.03

Nova Mentis Life Science Quick Ratio Historical Data

The historical data trend for Nova Mentis Life Science's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nova Mentis Life Science Quick Ratio Chart

Nova Mentis Life Science Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.98 2.65 6.73 0.78 1.11

Nova Mentis Life Science Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Mar24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.15 1.11 0.63 0.06 0.03

Competitive Comparison of Nova Mentis Life Science's Quick Ratio

For the Biotechnology subindustry, Nova Mentis Life Science's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nova Mentis Life Science's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nova Mentis Life Science's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Nova Mentis Life Science's Quick Ratio falls into.



Nova Mentis Life Science Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Nova Mentis Life Science's Quick Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Quick Ratio (A: Dec. 2022 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.282-0)/0.255
=1.11

Nova Mentis Life Science's Quick Ratio for the quarter that ended in Mar. 2024 is calculated as

Quick Ratio (Q: Mar. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.029-0)/0.995
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nova Mentis Life Science  (XCNQ:NOVA) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Nova Mentis Life Science Quick Ratio Related Terms

Thank you for viewing the detailed overview of Nova Mentis Life Science's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nova Mentis Life Science (XCNQ:NOVA) Business Description

Traded in Other Exchanges
Address
700-838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6
Nova Mentis Life Science Corp is a Canadian-based biotechnology company. It is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova uses psilocybin in the treatment of Fragile X Syndrome (FXS). The company's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs such as autism spectrum disorder (ASD) and FXS. It has one industry segment, being research and development of psilocybin, and in one geographic area, which is Canada.
Executives
Derek Lloyd Harry Ivany 10% Security Holder, Director, Senior Officer